Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Repotrectinib |
Trade Name | Augtyro |
Synonyms | TPX-0005 |
Drug Descriptions |
Augtyro (repotrectinib) is a multi-kinase inhibitor that demonstrates strong activity against Ros1, Ntrk1/2/3, and Alk, and also inhibits Jak2 and Src family kinases, resulting in tumor cell death (PMID: 30093503, PMID: 32269053). Augtyro (repotrectinib) is FDA-approved for use in patients with advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (FDA.gov). |
DrugClasses | ALK Inhibitor 32 JAK2 Inhibitor 17 ROS1 Inhibitor 20 SRC Inhibitor 31 Trk Receptor Inhibitor (Pan) 31 |
CAS Registry Number | 1802220-02-5 |
NCIT ID | C133821 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Gefitinib + Repotrectinib + Trametinib | Gefitinib Repotrectinib Trametinib | 0 | 0 |
Irinotecan + Repotrectinib + Temozolomide | Irinotecan Repotrectinib Temozolomide | 1 | 1 |
Osimertinib + Repotrectinib | Osimertinib Repotrectinib | 0 | 1 |
Repotrectinib | Repotrectinib | 32 | 3 |
Repotrectinib + SCH772984 | Repotrectinib SCH772984 | 0 | 0 |
Repotrectinib + Sotorasib | Repotrectinib Sotorasib | 0 | 0 |
Repotrectinib + Trametinib | Repotrectinib Trametinib | 0 | 1 |
Repotrectinib + Ulixertinib | Repotrectinib Ulixertinib | 0 | 0 |